A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (EudraCT-No.: 2018-004329-10)

Beteiligte Wissenschaftlerin:
Dr. rer. medic. M. Eveslage

Studienleitung:
Univ.-Prof. Dr. med. Martin Bögemann